BIONATURE

Among gynecological tumors, malignant uterine tumor (MUT) is the sixth most common cancer in women and the 15th most common cancer overall. There were approximately 382069 new cases and 89929 deaths attributed to this type worldwide in 2018. It was therefore the second and fourth leading cause of death from gynecological cancer in women in recent years and is expected to increase by more than 50% globally by 2040. Mortality rates are lowest in Central Asia, South and most of Africa. Survivors of MUT may experience treatment-related issues, including infertility, early onset of menopause, sexual problems, and lower limb lymphedema. WHO builds its own database from national modeling incidence estimates, using incidence ratios with a sampling method that relies on the calculation of a weighted or simple average of the most popular local rates applied to the population of a few regions or by an approximate estimate based on data provided by health establishments in neighboring countries. While in Algeria, existing statistical and epidemiological data and updated information on the pathology are insufficient. The objective of this work is to highlight the importance and the situation of the MUT in this country and to describe the different recent aspects (etiology, diagnostic and treatment) related to the disease.